Updated Perspectives on the Contribution of the Microbiome to the Pathogenesis of Mucositis Using the Mascc/Isoo Framework Publisher Pubmed



Stringer AM¹ ; Hargreaves BM¹ ; Mendes RA^{2, 3} ; Blijlevens NMA⁴ ; Bruno JS⁵ ; Joyce P⁶ ; Kamath S⁶ ; Laheij AMGA^{7, 8} ; Ottaviani G⁹ ; Secombe KR¹⁰ ; Tonkaboni A¹¹ ; Zadik Y^{12, 13} ; Bossi P^{14, 15} ; Wardill HR^{10, 16} Show Affiliations
Source: Supportive Care in Cancer Published:2024

Abstract

Advances in the treatment of cancer have significantly improved mortality rates; however, this has come at a cost, with many treatments still limited by their toxic side effects. Mucositis in both the mouth and gastrointestinal tract is common following many anti-cancer agents, manifesting as ulcerative lesions and associated symptoms throughout the alimentary tract. The pathogenesis of mucositis was first defined in 2004 by Sonis, and almost 20 years on, the model continues to be updated reflecting ongoing research initiatives and more sophisticated analytical techniques. The most recent update, published by the Multinational Association for Supportive Care in Cancer and the International Society for Oral Oncology (MASCC/ISOO), highlights the numerous co-occurring events that underpin mucositis development. Most notably, a role for the ecosystem of microorganisms that reside throughout the alimentary tract (the oral and gut microbiota) was explored, building on initial concepts proposed by Sonis. However, many questions remain regarding the true causal contribution of the microbiota and associated metabolome. This review aims to provide an overview of this rapidly evolving area, synthesizing current evidence on the microbiota’s contribution to mucositis development and progression, highlighting (i) components of the 5-phase model where the microbiome may be involved, (ii) methodological challenges that have hindered advances in this area, and (iii) opportunities for intervention. © The Author(s) 2024.